Neoadjuvant inetetamab combined with pertuzumab, paclitaxel and carboplatin for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study

被引：0
|
作者：
Chai, Y. [1 ]
Jiang, M. [1 ]
Liu, J. [1 ]
He, M. [1 ]
Wang, X. [2 ]
Wang, Y. [2 ]
Yang, X. [2 ]
Wang, J. [2 ]
Xu, B. [3 ]
Li, Q. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Med Oncol Dept, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Surg Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Med Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Oncol, Natl Canc Ctr, Canc Hosp, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.09.539
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360P
引用
收藏
页码：S327 / S327
页数：1
相关论文
共 50 条
  • [1] Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study.
    Chai, Yue
    Li, Qiao
    Liu, Jiaxuan
    Jiang, Mingxia
    He, Maiyue
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [2] Updated Results of a Phase II Study: Neoadjuvant Inetetamab Combined with Pertuzumab, Paclitaxel and Carboplatin for Locally Advanced HER2-Positive Breast Cancer
    Chai, Yue
    Liu, Jiaxuan
    Jiang, Mingxia
    He, Maiyue
    Wang, Xin
    Wang, Yipeng
    Yang, Xue
    Wang, Jing
    Xu, Binghe
    Li, Qiao
    CANCER RESEARCH, 2024, 84 (09)
  • [3] A propensity-matched analysis of the efficacy and safety of neoadjuvant inetetamab and pertuzumab with paclitaxel and carboplatin (TCbIP) on locally advanced HER2-positive breast cancer
    Jiang, Mingxia
    Chai, Yue
    Liu, Jiaxuan
    He, Maiyue
    Wang, Yipeng
    Xue, Yang
    Xing, Zeyu
    Zhang, Mengqi
    Zhou, Shihan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [4] Neoadjuvant inetetamab and pertuzumab with taxanes and carboplatin (TCbIP) In locally advanced HER2-positive breast cancer: a prospective cohort study with propensity-matched analysis
    Jiang, Mingxia
    Chai, Yue
    Liu, Jiaxuan
    He, Maiyue
    Wang, Yipeng
    Yang, Xue
    Xing, Zeyu
    Zhang, Mengqi
    Zhou, Shihan
    Ma, Fei
    Wang, Jiayu
    Yuan, Peng
    Xu, Binghe
    Li, Qiao
    BMC CANCER, 2024, 24 (01)
  • [5] Neoadjuvant Trastuzumab and Pyrotinib for Locally Advanced HER2-Positive Breast Cancer (NeoATP): Primary Analysis of a Phase II Study
    Yin, Wenjin
    Wang, Yaohui
    Wu, Ziping
    Ye, Yumei
    Zhou, Liheng
    Xu, Shuguang
    Lin, Yanping
    Du, Yueyao
    Yan, Tingting
    Yang, Fan
    Zhang, Jie
    Liu, Qiang
    Lu, Jinsong
    CLINICAL CANCER RESEARCH, 2022, 28 (17) : 3677 - 3685
  • [6] Neoadjuvant ixabepilone/carboplatin/trastuzumab in HER2-positive locally advanced breast cancer: A Sarah Cannon Research Institute phase II trial
    Zubkus, J. D.
    Daniel, D. B.
    Eakle, J. F.
    Bechhold, R. G.
    Shastry, M.
    Tucker, P. S.
    Burris, H. A.
    Hainsworth, J. D.
    Yardley, D. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [7] Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer
    Lavasani, Sayeh M.
    Somlo, George
    Yost, Susan E.
    Frankel, Paul H.
    Ruel, Christopher
    Cui, Yujie
    Murga, Mireya
    Tang, Aileen
    Martinez, Norma
    Kruper, Laura
    Tumyan, Lusine
    Schmolze, Daniel
    Yeon, Christina
    Yuan, Yuan
    Waisman, James R.
    Mortimer, Joanne
    CANCER, 2023, 129 (05) : 740 - 749
  • [8] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    Lopresti, M. L.
    Bian, J. J.
    Sakr, B. J.
    Strenger, R. S.
    Legare, R. D.
    Fenton, M.
    Witherby, S. M.
    Dizon, D. S.
    Pandya, S. V.
    Stuckey, A. R.
    Edmondson, D. A.
    Gass, J. S.
    Emmick, C. M.
    Graves, T. A.
    Cutitar, M.
    Olszewski, A. J.
    Sikov, W. M.
    BREAST CANCER RESEARCH AND TREATMENT, 2021, 189 (01) : 93 - 101
  • [9] Efficacy and tolerability of neoadjuvant Pertuzumab, Trastuzumab, and weekly Paclitaxel in Locally advanced Her-2 positive Breast cancer
    Gupta, Niraj
    Giblin, Erica
    Spivey, Tara
    Govert, Kristen
    Leagre, Christopher
    Liebross, Robert
    Tumati, Vasu
    Dugan, Thomas
    Yadav, Rina
    Henman, Patrick
    Beaudrie, Nick
    Bair, Tessa
    Durk, Jessica
    Hancock, Marjaorie
    Engle, Trisha
    Myers, Michelle
    Schneiders, Julie
    Tigges, Thomas
    CANCER RESEARCH, 2021, 81 (04)
  • [10] Neoadjuvant weekly paclitaxel and carboplatin with trastuzumab and pertuzumab in HER2-positive breast cancer: a Brown University Oncology Research Group (BrUOG) study
    M. L. Lopresti
    J. J. Bian
    B. J. Sakr
    R. S. Strenger
    R. D. Legare
    M. Fenton
    S. M. Witherby
    D. S. Dizon
    S. V. Pandya
    A. R. Stuckey
    D. A. Edmondson
    J. S. Gass
    C. M. Emmick
    T. A. Graves
    M. Cutitar
    A. J. Olszewski
    W. M. Sikov
    Breast Cancer Research and Treatment, 2021, 189 : 93 - 101
12345